YPrime has more than 10 years of experience designing cloud-based technological solutions to meet the needs of tomorrow’s clinical trials. Our eCOA and IRT solutions, clinical and data science expertise, patient insights, and clinical trial experience combine to improve the clinical trial experience for patients, sites, and sponsors. To learn more, visit https://www.yprime.com/

ABL, an Institut Mérieux Company, is a contract research and contract manufacturing organization offering full-service Immunology services to advance biologics from discovery to clinical phases. Established in 1961 as a biomedical research contractor for the government, ABL has contributed to the development of vaccines and therapeutics for major diseases and has developed a wide range of assays for various indications and treatments. To learn more, please visitwww.ablinc.com

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com.

AIQ’s TRAQinform IQ software quantifies and classifies lesion-specific treatment response and organ-specific toxicity from longitudinal imaging scans. It can deliver an early prediction of optimal/suboptimal responders to therapies allowing for optimal patient selection and more efficient go/no-go clinical decisions. It also provides concordance between multiple imaging modalities and radiotracers.

Axiom Healthcare Strategies is a boutique oncology think-tank, offering premier strategy and management consulting to biotechnology and pharmaceutical clients in the oncology and rare disease space. Our engagements focus exclusively on high-value contributions to our clients’ most critical challenges, and our depth of knowledge in oncology is unparalleled by any other firm. Learn more at www.axiomhcs.com.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at www.BostonGene.com

CanWell is a venture backed, clinical stage biotech company committed to developing FIC IO medicines. Our pipeline includes multiple modalities: small molecule, SMDC and ADC. To learn more, please visit www.canwellbiotech.com

Catalyst Oncology is a full-service, specialty contract research organization (CRO) built to serve the global biotech industry. Backed by leading retention rates and a culture rooted in its core values, Catalyst Oncology provides customers with teams experienced across all functions, knowledgeable in complex drug classes and study designs, and with data-centric methodologies that help bring next-generation therapies to cancer patients. Connect with Catalyst Oncology on LinkedIn. For more information, visit https://catalystcr.com/catalyst-oncology/oncology-cro/

The Center for Breakthrough Medicines (CBM) is an advanced therapy contract development and manufacturing organization (CDMO) uniquely positioned to enable pharma and biotech companies to develop, test and manufacture life-saving therapies on a global scale. CBM offers scalable, best-in-class capabilities for every stage of development – from IND through commercialization. To learn more, please visit www.breakthroughmedicines.com

Defence Therapeutics is a publicly-traded Canadian biotechnology company working on developing the next generation of vaccines and antibody-drug conjugate (“ADC”) products using its versatile proprietary platform ACCUMTM. The core of Defence Therapeutics platform is the ACCUMTM, a technology specially engineered to enable the design of novel cellular vaccines for the precision delivery of vaccine antigens and any ADCs in their intact form to target cells. As a result, significant increased efficacy and potency can be reached against catastrophic illness such as any type of cancers and infectious diseases. ACCUMTM DRUG THE UNDRUGGABLETM. To learn more, please visit www.defencetherapeutics.com

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide range of oncology targets. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance at least one innovative program into clinic each year.  To learn more please visit www.elpiscience.com

Emergence Therapeutics develops novel ADCs. Our lead program is a next-generation Nectin-4 ADC with superiority over enfortumab vedotin, a high-profile ADC for urothelial cancer. To learn more, please visit www.emergencetx.com